BACKGROUND: Treatment for primary CNS lymphoma (PCNSL) in the elderly is associated with lower response rates and higher risks of acute and late delayed toxicity as compared to younger patients. Temozolomide has emerged as a new alternative treatment for PCNSL and constitutes an attractive option for the elderly because of its favorable toxicity profile. In this study we report outcomes of a consecutive series of PCNSL elderly patients initially treated with an innovative regimen combining methotrexate and temozolomide without radiotherapy or intra-thecal chemotherapy. METHODS: Histologically confirmed newly-diagnosed PCNSL patients older than 60 years were included. An induction chemotherapy was initially given (methotrexate 3 g /m(2) on days 1, 10, and 20, and temozolomide 100 mg/m(2) on days 1-5). Patients achieving a partial or complete response proceeded to a maintenance phase (up to 5 monthly cycles of methotrexate 3 g/m(2) on day 1, and temozolomide 100 mg/m(2 )days 1-5). Non-responders were treated on an individual basis. RESULTS: Among the 23 included patients, a complete response was observed in 55%, and disease progressed in the other 45%. Median event-free survival was 8 months, and median overall survival was 35 months. Grades 3 or 4 toxicities included nephrotoxicity in three patients, and hematotoxicity in five; no neurotoxicity has been observed to date. One patient died while on treatment from complications of intestinal obstruction. CONCLUSION: Our efficacy results are comparable to other reported regimens, with the advantages of a favorable toxicity profile, and absence of intra-thecal chemotherapy. Prospective, controlled studies are warranted to confirm such results.
BACKGROUND: Treatment for primary CNS lymphoma (PCNSL) in the elderly is associated with lower response rates and higher risks of acute and late delayed toxicity as compared to younger patients. Temozolomide has emerged as a new alternative treatment for PCNSL and constitutes an attractive option for the elderly because of its favorable toxicity profile. In this study we report outcomes of a consecutive series of PCNSL elderly patients initially treated with an innovative regimen combining methotrexate and temozolomide without radiotherapy or intra-thecal chemotherapy. METHODS: Histologically confirmed newly-diagnosed PCNSL patients older than 60 years were included. An induction chemotherapy was initially given (methotrexate 3 g /m(2) on days 1, 10, and 20, and temozolomide 100 mg/m(2) on days 1-5). Patients achieving a partial or complete response proceeded to a maintenance phase (up to 5 monthly cycles of methotrexate 3 g/m(2) on day 1, and temozolomide 100 mg/m(2 )days 1-5). Non-responders were treated on an individual basis. RESULTS: Among the 23 included patients, a complete response was observed in 55%, and disease progressed in the other 45%. Median event-free survival was 8 months, and median overall survival was 35 months. Grades 3 or 4 toxicities included nephrotoxicity in three patients, and hematotoxicity in five; no neurotoxicity has been observed to date. One patient died while on treatment from complications of intestinal obstruction. CONCLUSION: Our efficacy results are comparable to other reported regimens, with the advantages of a favorable toxicity profile, and absence of intra-thecal chemotherapy. Prospective, controlled studies are warranted to confirm such results.
Authors: Ulrich Herrlinger; Wilhelm Küker; Martin Uhl; Hans-Peter Blaicher; Hans-Otto Karnath; Lothar Kanz; Michael Bamberg; Michael Weller Journal: Ann Neurol Date: 2005-06 Impact factor: 10.422
Authors: Antonio M P Omuro; Leah S Ben-Porat; Katherine S Panageas; Amy K Kim; Denise D Correa; Joachim Yahalom; Lisa M Deangelis; Lauren E Abrey Journal: Arch Neurol Date: 2005-10
Authors: M Montemurro; T Kiefer; F Schüler; H K Al-Ali; H-H Wolf; R Herbst; A Haas; K Helke; A Theilig; C Lotze; C Hirt; D Niederwieser; M Schwenke; W H Krüger; G Dölken Journal: Ann Oncol Date: 2006-12-21 Impact factor: 32.976
Authors: Hendrik Pels; Ingo G H Schmidt-Wolf; Axel Glasmacher; Holger Schulz; Andreas Engert; Volker Diehl; Anton Zellner; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Martina Deckert; Rolf Fimmers; Christoph Helmstaedter; Aslihan Atasoy; Thomas Klockgether; Uwe Schlegel Journal: J Clin Oncol Date: 2003-11-03 Impact factor: 44.544
Authors: Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jennifer A Quinn; Alan D Austin; James E Herndon; Roger E McLendon; Henry S Friedman Journal: J Neurooncol Date: 2013-05-18 Impact factor: 4.130
Authors: L Toffolatti; E Scquizzato; S Cavallin; F Canal; M Scarpa; P M Stefani; F Gherlinzoni; A P Dei Tos Journal: Virchows Arch Date: 2014-07-17 Impact factor: 4.064
Authors: Delia Kurzwelly; Martin Glas; Patrick Roth; Elke Weimann; Hanns Lohner; Andreas Waha; Martin Schabet; Guido Reifenberger; Michael Weller; Ulrich Herrlinger Journal: J Neurooncol Date: 2009-10-20 Impact factor: 4.130